Shots:
- Formycon has reported that Klinge Biopharma, holder of global rights to FYB203/Ahzantive (aflibercept-mrbb), has signed an exclusive licensing deal with Valorum Biologics for commercialization across the US and Canada
- As per the deal, Klinge will receive upfront, milestone, and royalty payments on net sales. Formycon will receive a mid-single—to low-double-digit percentage of all payments made to Klinge. It will manage the FYB203 supply chain for Klinge and receive service fees plus volume-based profit.
- ATHOS KG, a key Formycon shareholder, is leading Valorum’s Series A funding, showing confidence in Valorum’s strategy and FYB203’s potential. Canadian approval of FYB203 is expected by YE’25
Ref: Formycon | Image: Valorum Biologics and Formycon | Press Release
Related News:-
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
